PharmaTher has successfully completed the evaluation of a patented hydrogel-forming microneedle patch to deliver Ketamine as a potential next-generation treatment for neuropsychiatric, neurodegenerative and pain disorders. This de-risking milestone supports the Company’s expansion in finalizing IND-enabling studies and the clinical manufacturing scale up to support FDA and international regulatory submissions. Validation and tech transfer activities to support clinical studies are in progress.
Connect With Us
PharmaTher Holdings Ltd. 82 Richmond Street East Toronto, Ontario Canada M5C 1P1